Carl Franzetti, DO
Family Medicine · Bronx, NYNPI 1124111521
Payments from drug & device makers
Across 324 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$699
- Astellas Pharma US Inc$650
- Avanir Pharmaceuticals, Inc.$491
- GSK$452
- AbbVie$429
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,20097%
- Education$2223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $1,114 |
| AstraZeneca | 40 | $699 |
| Astellas Pharma US Inc | 25 | $650 |
| Avanir Pharmaceuticals, Inc. | 24 | $491 |
| GSK | 21 | $452 |
| AbbVie(2 entities) | 21 | $429 |
| Sanofi-aventis U.S. LLC | 13 | $245 |
| Novartis | 13 | $230 |
| Lilly USA, LLC | 13 | $215 |
| Amgen(2 entities) | 9 | $202 |
| Boehringer Ingelheim | 10 | $196 |
| Gilead | 9 | $186 |
| Amarin Pharma, Inc. | 9 | $175 |
| Pfizer | 9 | $140 |
| Otsuka America Pharmaceutical, Inc. | 4 | $114 |
| Dexcom, Inc. | 4 | $114 |
| Bayer | 5 | $105 |
| Hologic Sales And Service, LLC | 4 | $84 |
| Johnson & Johnson | 4 | $82 |
| Genentech USA, Inc. | 3 | $61 |
| Abbott | 3 | $51 |
| Intra-sana Laboratories | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Exact Sciences | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Almatica Pharma LLC | 1 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Althera Pharmaceuticals LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
How this compares
$6,423 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $145,189 |
| JardianceEmpagliflozin | 137 | $87,325 |
| MounjaroTirzepatide | 47 | $79,048 |
| RexultiBrexpiprazole | 92 | $68,929 |
| TrulicityDulaglutide | 82 | $63,196 |
| OzempicSemaglutide | 52 | $61,808 |
| XareltoRivaroxaban | 136 | $61,393 |
| FarxigaDapagliflozin Propanediol | 95 | $56,304 |
| EntrestoSacubitril/Valsartan | 56 | $39,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $32,079 |
| NuedextaDextromethorphan Hbr/Quinidine | 36 | $27,312 |
| JanuviaSitagliptin Phosphate | 45 | $27,078 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $17,306 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $13,684 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $10,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $140 | $145,189256 claims |
| Lilly USA, LLCMounjaro, Trulicity | $215 | $142,245129 claims |
| Boehringer IngelheimJardiance, Tradjenta | $196 | $94,035153 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $114 | $68,92992 claims |
| Novo NordiskOzempic | $1,114 | $61,80852 claims |
| Johnson & JohnsonXarelto | $82 | $61,393136 claims |
| AstraZenecaFarxiga, Symbicort | $699 | $59,829109 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $452 | $49,38566 claims |
| NovartisEntresto | $230 | $39,75056 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $491 | $27,31236 claims |
| MerckJanuvia | $17 | $27,07845 claims |
| AbbVieLinzess, Restasis | $429 | $18,79436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bronx
- Eugene SchiffBronx$184K
- Hui-Li HuangBronx$41K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.